克拉霉素联合兰索拉唑治疗幽门螺杆菌感染性胃炎的临床疗效及有效率影响分析

Clinical Efficacy and Efficacy of Clarithromycin Combined with Lansoprazole in the Treatment of Helicobacter Pylori Infection Gastritis

目的:探究克拉霉素联合兰索拉唑治疗幽门螺杆菌感染性胃炎的临床疗效及有效率。方法:选择我院2016年6月至2017年8月期间收治的76例幽门螺杆菌感染性胃炎患者,76例患者按照随机数字表方法平均分为观察组和对照组,每组患者38例。对照组选择常规治疗,观察组选择克拉霉素联合兰索拉唑治疗,对比两组患者治疗后的临床效果。结果:①观察组患者治疗总有效率为97.37%,对照组患者治疗总有效率为81.58%,组间数据经过统计对比P<0.05,形成统计学意义;②观察组患者经过治疗后幽门螺杆菌清除率为92.11%,对照组患者经过治疗后幽门螺杆菌清除率为73.68%,组间数据差异显著;③观察组患者不良反应发生率为5.26%,对照组患者不良反应发生率为23.68%,组间数据差异显著,形成统计学意义。结论:幽门螺杆菌感染性胃炎患者经克拉霉素联合兰索拉唑治疗后效果显著,提升幽门螺杆菌清除率,安全可靠性良好。

Objective:Objective:To investigate the clinical efficacy and effective rate of clarithromycin combined with lansoprazole in the treatment of Helicobacter pylori infection gastritis.Methods:From June 2016 to August 2017,76 patients with Helicobacter pylori infection gastritis were divided into observation group(n=38)and control group(n=38).The control group was treated with conventional therapy,and the observation group with clarithromycin combined with lansoprazole.Results:The total effective rate was 97.37%in the observation group and 81%in the control group.The data between groups were statistically significant after statistical comparison(P<0.05).The clearance rate of Helicobacter pylori was 92.11%in the observation group and 73.68%in the control group.The incidence of adverse reactions was 5.26%in the observation group and 23.68%in the control group.Conclusion:The efficacy of clarithromycin combined with lansoprazole in the treatment of Helicobacter pylori infection gastritis is remarkable,and the clearance rate of Helicobacter pylori is improved and the safety and reliability are good.